| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/09/2003 | WO2003002136A2 Stable formulation of modified glp-1 |
| 01/09/2003 | WO2003002114A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | WO2003002103A2 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002094A2 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002091A2 Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same |
| 01/09/2003 | WO2003002090A1 Immunopotentiator for mammary gland of dairy cows containing lactoferrin as an active ingredient |
| 01/09/2003 | WO2003002087A1 Use of a lys-pro-val (kpv) tripeptide in cosmetics |
| 01/09/2003 | WO2003002086A2 Use of the tripeptide lys-pro-val(kpv) for improving the skin barrier function |
| 01/09/2003 | WO2003002076A1 Composite powders and skin preparations for external use containing the same |
| 01/09/2003 | WO2003002068A2 Diagnosis and treatment of cancer |
| 01/09/2003 | WO2003002061A2 Compositions and methods for treating atherosclerosis |
| 01/09/2003 | WO2003001983A2 Methods for diagnosing and treating a disease mediated by decreased mmp-2 function |
| 01/09/2003 | WO2003001892A2 Heparin-binding factors in tissue repair, regeneration and bioengineering |
| 01/09/2003 | WO2003001883A2 Gaba b1a receptor disruptions, compositions and methods relating thereto |
| 01/09/2003 | WO2003001881A2 Cell-based high-throughput screening methods |
| 01/09/2003 | WO2003001880A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/09/2003 | WO2002098345A8 Use of an antioxidant for treating and/or preventing surface ocular disorders |
| 01/09/2003 | WO2002083716A3 Type b botulism toxin inhibitors |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002078619A3 Alkynylated single-strand oligonucleotide and uses thereof |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002071062A9 Diagnosis and treatment of inflammation and hyperactive immune conditions |
| 01/09/2003 | WO2002069994A3 Combined use of derivatives of glp-1 analogs and ppar ligands |
| 01/09/2003 | WO2002060486A3 Controlled release microsphere system for administration of drug to the eye |
| 01/09/2003 | WO2002046423A3 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002042437A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/09/2003 | WO2002038743A3 Deaminase catalyzing the removal of the cyclopropyl moiety from abacavir-mp |
| 01/09/2003 | WO2002036625A3 Prokineticin polypeptides, related compositions and methods |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 01/09/2003 | WO2002032943A3 Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| 01/09/2003 | WO2002031142A3 Antisense nucleic acid against alphav integrin |
| 01/09/2003 | WO2002026997A3 Dsp-16 dual-specificity phosphatase |
| 01/09/2003 | WO2002024726A3 Olfactory and pheromones g-protein coupled receptors |
| 01/09/2003 | WO2002020558A3 Method for binding, in solution, a peptide and a lipophilic vector and uses thereof |
| 01/09/2003 | WO2002014485A3 Kallikrein gene |
| 01/09/2003 | WO2002013855A3 Vaccines containing ribavirin and methods of use thereof |
| 01/09/2003 | WO2002012327A3 Compositions and methods for the therapy and diagnosis of pancreatic cancer |
| 01/09/2003 | WO2002012282A3 Novel ebi-3-alt protein and nucleic acid molecules and uses therefor |
| 01/09/2003 | WO2002009762A3 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection |
| 01/09/2003 | WO2002008283A3 Lp120 polypeptides and therapeutic uses thereof |
| 01/09/2003 | WO2002008251A3 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/09/2003 | WO2002004518A3 Human neuropeptide y-like g protein-coupled receptor |
| 01/09/2003 | WO2002004510A3 Gtp-binding proteins |
| 01/09/2003 | WO2002003970A2 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001098294A3 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 01/09/2003 | WO2001097828A3 Rhob as a suppressor of cancer cell growth and cell transformation |
| 01/09/2003 | WO2001097826A3 Hemostatic compositions, devices and methods |
| 01/09/2003 | WO2001092512A3 Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides |
| 01/09/2003 | WO2001081376A3 Apo-ai/aii peptide derivatives |
| 01/09/2003 | WO2001079489A8 39228, a human alcohol dehydrogenase and uses therefor |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001074846A3 Peptides mimicking the biological activity of steroid hormones and their uses |
| 01/09/2003 | WO2001070776A3 Nimr compositions and their methods of use |
| 01/09/2003 | WO2001068841A3 Human dcc-like proteins |
| 01/09/2003 | WO2001067100A9 Bax degradation involvement in tumor survival and progression |
| 01/09/2003 | WO2001066764A9 16835, a human phospholipase c and uses thereof |
| 01/09/2003 | WO2001066759A9 26886, a novel carnitine acyltransferase family member and uses therefor |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | WO2001057278A3 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human hela cells or other human cervical epithelial cells |
| 01/09/2003 | WO2001057276A3 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human bone marrow |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001056532A9 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 01/09/2003 | WO2001055411A9 Human sulfatases |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | WO2001055333A9 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 01/09/2003 | US20030009781 Animal model for use in the treatment of pain and anxiety disorders |
| 01/09/2003 | US20030009777 Using galanin agonist in the generation of medicament for the treatment of nerve damage |
| 01/09/2003 | US20030009023 Isolation and method of using tissue growth-inducing Frzb protein |
| 01/09/2003 | US20030009021 Novel human proteases and polynucleotides encoding the same |
| 01/09/2003 | US20030009019 Novel telomerase |
| 01/09/2003 | US20030009013 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2003 | US20030009012 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2003 | US20030009010 As vaccines for therapy and prophylaxis of Haemophilus influenzae infection |
| 01/09/2003 | US20030009009 Modified cytokine receptor protein |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008900 Compounds and compositions for delivering active agents |
| 01/09/2003 | US20030008875 Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system |
| 01/09/2003 | US20030008864 Treatment of diseases involving cyst formation |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008838 Method of increasing endogenous leptin production |
| 01/09/2003 | US20030008837 Therapy |
| 01/09/2003 | US20030008836 Eukaryotic gene expression cassette and uses thereof |
| 01/09/2003 | US20030008830 Medicinal dressings that provide an advanced healing environment for burn wounds |
| 01/09/2003 | US20030008829 For therapy and prophylaxis of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis, psoriasis |
| 01/09/2003 | US20030008828 Diagnostic kits; for therapy of viral infection; as assat standard or reagent |
| 01/09/2003 | US20030008827 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/09/2003 | US20030008824 Stimulation of vascularization with VEGF-B |
| 01/09/2003 | US20030008823 For determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT1F receptor |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008821 Methods of preventing UVB-induced skin damage |
| 01/09/2003 | US20030008820 Methods and products related to FGF dimerization |
| 01/09/2003 | US20030008819 Targeting endothelium for tissue-specific delivery of agents |
| 01/09/2003 | US20030008818 Compositions containing inclusion complexes |
| 01/09/2003 | US20030008817 Cross-link reversing agent |
| 01/09/2003 | US20030008816 Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |